Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BellRock Brands Inc DXBRF

BellRock Brands Inc. (BellRock) is a cannabis consumer packaged goods (CPG) and intellectual property platform company. The Company is a multi-state cannabis house of brands possessing product portfolios, developed through research and differentiated intellectual property. The Company has approximately 100 products available through its two flagship brands, Dixie Brands and Mary’s Medicinals... see more

GREY:DXBRF - Post Discussion

BellRock Brands Inc > News Release
View:
Post by Idvhmz123 on Feb 17, 2021 7:09am

News Release

TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (WeedMD or the Company), a federally licensed producer and distributor of medical-grade cannabis, is pleased to announce the Canadian launch of acclaimed U.S.-based wellness brand Marys Medicinals, part of the Marys Brands ("Marys) portfolio, and a BellRock Brands Inc. ("BellRock") (CSE: BRCK.U) company. As the exclusive manufacturer and distributor for Marys Medicinals suite of products in Canada, WeedMD will launch Marys Medicinals Transdermal Compound topical as its first release, with expected availability to the Companys Starseed Medicinal patients starting late February, 2021. WeedMD will expand availability starting with Ontario expected in March 2021, to be followed by additional provinces. The launch will eventually expand to include new product formats, including Marys Medicinals transdermal gels and patches, and will become available to both medical and direct-to-consumer markets. WeedMD is processing Marys Medicinals compound in-house at its Aylmer, ON-based extraction hub, using its own indoor and outdoor-input biomass. The Companys product development and extraction teams are using Marys proprietary and patented technology which calls for extracting CBD, THC and CBN the active cannabinoid ingredients used to produce rich transdermal compounds. The extracts and resins are formulated together with naturally sourced mango butter, locally-sourced beeswax and menthol ingredients to produce Marys Medicinals topical products, which have been shown to provide targeted relief and deeper penetration than traditional cannabis topicals. Were excited to be launching Marys Medicinals acclaimed therapeutic-based cannabis products in Canada - an important milestone as we expand our line-up with trusted Cannabis 2.0 additions, said George Scorsis, Executive Chairman and Interim CEO, WeedMD. We set out to produce CBD, THC and CBN-rich extracts in order to formulate new cannabis formats for an underserved patient and consumer segment looking for high-value, premium self-care products. As Marys Medicinals exclusive partner, we are proud to be introducing and delivering these high-calibre topical products to our local markets and taking a dominant position in this segment with a trusted brand. Canada has long been regarded as a pioneering cannabis nation and were thrilled to be expanding Marys Medicinals product reach into this important market alongside our local partner WeedMD, said Chuck Smith, CEO of BellRock. Our collaboration comes at a time when there is a greater acceptance of diverse and novel cannabis delivery methods and an evolving consumer base. Were looking forward to expanding into new and exciting distribution channels across the continent with such a lauded partner. With Marys Medicinals product release on the Companys medical channel, Starseed Medicinal, WeedMD expects to gather important insights, data and consumer feedback prior to its retail release. Starseed patients with benefits coverage may be able to purchase topicals via insured benefits. Current third-party* data suggest over 75% of Canadians new to cannabis are interested in trying cannabis topicals as a relief for certain indications including as an analgesic alternative. A recent research report from RBC Capital Markets forecasts the 2021 Canadian concentrates-topicals sales market to be valued at approximately C$227 million, as cannabis-curious Canadians look to try non-intoxicating, next-generation cannabis products. Marys Medicinals Patented Formulations & More about CBN Products Marys Medicinals is widely recognized in legalized U.S. states, including its home state of Colorado, as well as Nevada, Michigan, Illinois, Maryland, Oklahoma and Florida, for its innovative portfolio of cannabis brands. In August 2020, WeedMD and Marys announced an exclusive agreement to produce and distribute Marys Medicinals products in Canada. WeedMD is now producing CBN (cannabinol) isolates, a minor cannabinoid found in cannabis, though in trace amounts when compared to dominant cannabinoids, THC and CBD. Research suggests CBN may have potential to alter pain signals and may possess sedative properties amongst other properties. The Company is also currently assessing CBN product applications in addition to topical compounds, such as patches and transdermal gels, tinctures and vaporizable products for its medical and adult-use portfolios under the Marys Medicinals brand. WeedMD has further completed volume trials to produce CBD isolate. The refined, crystalline form of the cannabinoid boasts near-pure CBD concentrations, upwards of 99 per cent potency. The Company is exploring future product potential for CBD isolate, including high-potency oils, sprays and prepared edibles for its Starseed Medicinal and adult-use Color Cannabis and Saturday Cannabis brands. Access WeedMDs 2021 Shareholder Newsletter here. Updated investor presentation and corporate deck can be found here. *Source: Deloitte - Nurturing New Growth, Canada Gets Ready for Cannabis 2.0 (2019) About BellRock Brands, parent company to Marys Brands BellRock Brands is a brand and IP focused CPG company that possesses one of the industry's broadest branded product portfolios catering to the growing and ever-evolving cannabis consumer. BellRock's portfolio consists of two iconic cannabis brands with deep history, Mary's Brands (a pioneer in the Health & Wellness segment since 2013) and Dixie (a market leading cannabis-infused edibles brand since 2010), as well as two growing, California-based brands, Rebel Coast and Dfonc. Together, the BellRock brands offer a vast spectrum of high-quality cannabis-centric consumer packaged goods. With 11 brands and over 200 SKUs, BellRock reaches nearly every key consumer group and addresses the needs of a diverse cannabis consumer base. For more information, visit www.bellrockbrands.com. Marys Brands, founded in 2013 and known for its award-winning transdermal technology found in its cannabis patch and transdermal dispensing gel pen, is dedicated to pioneering and delivering natural, THC, CBD and other cannabinoid-infused products to positively impact the lives of both people and pets. To learn more about Marys Brands, visit www.marysbrands.com.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities